期刊
ONCOLOGIST
卷 17, 期 10, 页码 1240-1245出版社
ALPHAMED PRESS
DOI: 10.1634/theoncologist.2012-0169
关键词
Breast cancer; Body composition; Clinical outcome
类别
资金
- Novartis
- BIPAR Sciences
- Bristol-Myers Squibb
- National Institutes of Health [RO1NR010162-01A1, RO1CA1222292.01, RO1CA124481-01]
- American Cancer Society [PEP-08-299-01-PC1]
Introduction. Overweight women diagnosed with breast cancer have greater recurrence and mortality risks. Recent studies in advanced cancer showed that the combination of sarcopenia and an overweight or obese body mass index (BMI) is associated with poor clinical outcomes. Objectives. To compare pathological complete response (pCR) cases with controls and evaluate associations among a pCR, survival outcome, and sarcopenia as well as the combination of both sarcopenia and a BMI >= 25 kg/m(2). Methods. Sixty-seven breast cancer patients with a pCR to neoadjuvant chemotherapy (NC) were matched with controls who did not have a pCR to NC. Patients were matched by age, Black's nuclear grading system, clinical cancer stage, and estrogen receptor and progesterone receptor status. Body composition was analyzed using computed tomography images taken prior to NC. Results. BMI was associated with pCR. Among normal weight patients, the pCR rate was higher in sarcopenic patients and the progression-free survival (PFS) interval was significantly longer than in overweight or obese BMI patients. The death hazard was 2% higher for each unit higher skeletal muscle index and 0.6% higher for each unit higher visceral adipose tissue. Conclusions. Overweight patients treated with NC had a lower pCR rate and shorter PFS time. Among patients with a normal BMI, the pCR rate was better in sarcopenic patients. More research is required to evaluate the negative impact of sarcopenic obesity on prognosis and the contributors to better response rates in operable, normal weight breast cancer patients with sarcopenia. The Oncologist 2012; 17: 1240-1245
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据